It has been reported that leptin-replacement therapy delayed neurological regression or allowed better seizure control in patients with PELD (Sánchez-Iglesias et al., 2019; Pedicelli et al., 2020; Araújo-Vilar et al., 2018). Here, LEP is linked to severe neurodegenerative syndrome with lipodystrophy.